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Abstract 
Three-dimensional printing has become a feasible manufacturing technique for pharmaceutical products 
providing cheap and accurate freeform systems with a great potential for personalized-dose drugs. Fused 
Deposition Modeling (FDM) highlights among other 3D technologies due to its low cost and easy to 
operate but, until now, it has the drawbacks of the low drug loaded and the impossibility to print 
thermosensitive drugs. So, intermediate processes such as hot melt extrusion are frequently associated 
with FDM. Here, pharmaceutical dosage forms have been manufactured for the first time with a 3D 
printer combining two different printing technologies: FDM and injection volume filling (IVF), 
performing customized extruded scaffolds in which a liquid or semisolid system can be injected at room 
temperature. A model drug and a pH-sensitive polymer were successfully incorporated during the 
construction of the extruded backbone of the systems, called printfills (printed systems filled with a 
liquid or semisolid). SEM microphotographs of printfills show the sealing of the structure in the 
perimeter and the homogeneity of the colonic film formed in the upper side. Thus, the addition of the 
pH-sensitive polymer does not need an additional process in a fluidized bed or coating pan. Results from 
drug release studies performed at different pH confirm the ability of printfills for colon-specific drug 
delivery. Therefore, IVF technology complements FDM, solving its main limitations providing an easy, 
automatized and versatile technology to manufacture tailored drug delivery platforms, avoiding other 
intermediate processes.  
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1. Introduction  
Three-dimensional printing is a manufacturing technique that has been introduced in the pharmaceutical 
field in the ´90s [1]. 3D printing includes a wide number of technologies which are based on digitally-
controlled depositing of materials to produce freeform geometries [2]. The application of this technique 
in pharmaceuticals represents an interesting tool for designing simple, accurate, cheap, structured and 
personalized-dose medicines. The personalization of the dose could allow the optimization of the dose 
considering the gender, age, weight, state of the disease and the genetic profile. This aspect gains 
importance in geriatric and pediatric patients whose physiological needs are very particular, which 
entails a treatment more in line with their specific needs [3–5]. Several studies have demonstrated the 
potential of this technology to develop different oral dosing and transdermal systems [6–11]. Thus, this 
technology provides key advantages over traditional manufacturing of drug delivery and testing systems 
[12]. However, some drawbacks that have been pointed out include the low printing speed, the lack of 
quality control procedures for printed systems manufactured at hospitals or pharmacy, or even the 
possible risk of cyber-attacks on the computer which controls the printing process, jeopardizing the 
recipe. Moreover, due to its low production and upfront development cost, further studies and an 
improvement of these technologies are needed to scale up the production in the near future. 
Notwithstanding the above, from a commercial point of view, 3D printing can be considered as a viable 
option of manufacture for oral dosage forms. In this sense, USFDA is working in order to frame 
regulations for 3D printing pharmaceutical products [13]. 
Among the different 3D printing techniques, fused deposition modeling (FDM) is attracting the interest 
of researchers in pharmaceutical formulations design due to its low cost, easy to operate and the ability 
to elaborate hollow objects [9,14]. This technology works extruding a polymeric filament with a well-
defined and consistent diameter through robotically-actuated nozzles and then solidifying it on a build 
plate [14,15]. As a result, drug release profiles from FDM printed tablets are easily controlled by varying 
factors such as geometry, polymer selection or drug load [15,16]. However, FDM has the limitation of 
the impossibility to print thermally sensitive drugs [7,17] and the need to incorporate the drug to the 
polymeric filament as a previous step of manufacture. Drug loading filaments have been developed 
firstly by impregnating water-soluble filaments in concentrated alcoholic solutions of drugs, but 
achieving poor drug loading (< 2%) [7,9,18,19]. Later, hot melt extrusion technique has provided better 
drug loaded strands [20,21]. These blend filaments have to accomplish with the requirements of the 3D 
printers (flexibility, circular cross-section and diameter tolerance (1.75±0.05 mm)) needing very often 
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the addition of plasticizers to enhance the mechanical properties of the filaments [22]. Regarding the 
limitation of the extrusion temperature, some researchers have achieved to extrude filaments at 65ºC, but 
the temperature applied later for printing had to be higher (90ºC), due to the short time that material pass 
through the heating chamber of the 3D printer [17,22,23].   
Dual or multiple extruder 3D printers are also available in the market allowing obtaining composite 
tablets with different drug profiles [9,24]. Recently, some researchers have modified these dual FDM to 
include a syringe based dispenser to incorporate liquids or pastes to the systems [8,25]. Nevertheless, to 
our knowledge, the combination of two different 3D printing technologies in a marketed printer to 
manufacture pharmaceutical formulations has not been already reported. An optimized bioprinter 
(REGEMAT 3D, Granada, Spain) incorporates two different 3D printing techniques: FDM and Injection 
Volume Filling (IVF), performing a customized extruded scaffold in which a liquid or semisolid system 
is injected. IVF allows incorporating solutions/dispersions at room temperature to the extruded scaffold. 
Until now, this bioprinter has been mainly focused on tissue regeneration applications, adding cells to 
the extruded system [26]. We hypothesize that the integration of FDM and IVF could offer an easy, 
automatized and versatile technology to manufacture tailored drug delivery platforms.  
The present paper describes the preparation of a new kind of printed pharmaceutical dosage forms that 
we have called printfills (printed systems filled with a liquid or semisolid), applying for the first time 
this new technology to the manufacture of dosage forms.  
Among modified release drug delivery systems, colon targeting remains a very promising area for 
protein delivery and the treatment of colonic diseases, such as Crohn's disease, colon cancer or 
ulcerative colitis. This allows reducing the amount of drug necessary, causing fewer side effects [27]. In 
addition, several studies have shown that many drugs have a very good absorption in the colon, then the 
development of new specialized formulations in this region is crucial [27–29]. The manufacture of 
enteric printed systems has been reported including the coating of 3D printed cores with an enteric 
polymer (Eudragit L100) in a fluid bed coater [30] or producing enteric filaments by HME with 
polyacrylic derivatives or hydroxypropylmethylcellulose acetate succinate [31]. In both cases, an 
additional step in the manufacture of the printed systems is needed to add the enteric polymer.  
Thus, combining two 3D printing techniques in the same printer, the addition of the delaying polymer 
can be carried out with IVF while the scaffold is being developed with FDM as a continuous 
manufacturing process. Therefore, this printer would provide a saving of energy, time and space, 
compared to traditional process. 
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The aim of this work is to design and characterize colon-specific drug delivery systems manufactured in 
a simple and automated 3D printer which combines two different 3D printing technologies: FDM and 
IVF. The model drug and the pH-sensitive polymer will be incorporated at room temperature during the 
construction of the extruded backbone of three-dimensional tablets. Drug release behavior of these 
printfills will be analyzed in order to evaluate their ability to control the drug release. 
2. Materials and methods 
2.1. Materials  
Polylactic acid (PLA) was chosen as biodegradable thermoplastic printer filament for FDM (melting 
point 220ºC, density 1.25 g/cm
3
), supplied by Leon3D (Spain). Hydroxypropyl methylcellulose 
METHOCEL™ K4M (Colorcon Ltd., UK) was used as hydrophilic polymer to prepare drug-loaded 
hydrogels for IVF. Anhydrous theophylline (Acofarma, Spain) has been used as a model drug. Eudragit 
FS30D (Evonik, Germany) was chosen as delaying release polymer. 
2.2. Methods 
2.2.1. Preparation of drug printable ink 
HPMC (1% w/v) gel was prepared by adding powdered HPMC into 100 ml of hot water (90º C) and 
thoroughly agitating until a dispersion was formed. The dispersion was cooled with ice and stored in a 
refrigerator for 24 h until a smooth homogenous gel, free from air bubbles and aggregates, was formed. 
Volumes of HPMC gel and ethanol at a ratio of 25:75 (v/v) were thoroughly mixed to form a hydro-
alcoholic gel. Ethanol is used to retard swelling providing suitable injectability [32]. Finally, 
theophylline was added until complete dissolution (20 mg/ml). 
2.2.2. 3D printing process 
Printfills were manufactured with a REGEMAT 3D V1 printer (Regemat 3D S.L., Spain) with FDM and 
IVF techniques. The software REGEMAT 3D DESIGNER was used to design the 3D printed systems. 
Printable gel and Eudragit FS30D dispersion were loaded into two syringes of IVF process, using 0.25 
and 0.58 mm diameter tips, respectively. 
The printing settings for FDM were as follows: layer thickness 0.35 mm, perimeter speed 8 mm/s, infill 
speed 8 mm/s and feeding rate 1.2 mm/s to produce printfills with height of 7.35 mm and diameter of 14 
mm. 
IVF parameters were: deposit speed 1 μl/s, retract speed 1 μl/s and purge 50 μl for both syringes. 
Printfills were extruded on a glass slide layer by layer, according to the digitally designed object (Figure 
1). Extruded scaffolds were formed by 21 layers with 4 sealing perimeters for each one. Firstly, FDM 
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nozzle extruded 2 bottom solid layers. In the third layer, the extruder builds parallel lines separated by 
1.2 mm from each other. In the fourth layer, the extruder repeats the process with the difference that the 
lines are built in a perpendicular direction with respect to the lower ones. So, a quadrilateral mesh of 1.2 
x 1.2 mm is created. The process continues similarly until the 18th layer, when extruder automatically 
moves away and IVF syringe with printable gel injects a volume of 200 μl of hydroalcoholic solution in 
4 different points digitally defined to ensure the gel distribution inside the scaffold. The porous structure 
of the internal mesh allows the diffusion of the drug ink. Then, 3 additional layers are built by FDM 
extruder to complete the scaffold and the second syringe injects 350 μl of Eudragit FS30D dispersion 
into the top layer of the structure.  
All the steps including contribution of FDM extruder and the two IVF syringes were automatically 
performed, building the structure without drying process between them.  
Once the structures were completely built, printfills were dried at room temperature to evaporate solvent 
for 24 h. 
       
Figure 1. Digital design of printfills with drug represented by red points and the enteric polymer represented as green ones. 
 
In a second series of experiments, printed scaffolds without Eudragit FS30D were manufactured in order 
to check the drug release profile from these systems, for comparison purposes. 
2.2.3. Physical tests of printed systems 
Printfills were weighted in a precision balance (Scaltec, type SBC31) and thickness and diameter were 
measured using a digital micrometer (Comecta, SA).  
2.2.4. Scanning electron microscopy (SEM) 
The surface and transversal section of printfills were evaluated in the Microscopy Service of the CITIUS 
in the University of Seville by using scanning electron microscopy (SEM) with a FEI TENEO electronic 
microscope (FEI Company, USA), operating at 5 kV. Printed tablets were coated with a 12 nm thin 
Pt/Pd layer with Leica EM SCD500 high vacuum sputter coater.  
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2.2.5. Determination of drug loading 
The printed system was placed in a volumetric flask (1L deionized water adjusted to pH 7.5 with 2 M 
NaOH in order to dissolve the polymer) under magnetic stirring until complete dissolution (n = 3). 
Samples were withdrawn and filtered through 0.45 mm filters (Millipore Ltd., Ireland). The 
concentration of drug was determined by UV–Vis spectrophotometer Agilent 8453 (California, USA) at 
272 nm [33]. 
2.2.6. Dissolution testing of printed tablets and modelling 
The dissolution studies were carried out using a USP Apparatus I Sotax AT7 smart (Allschwil, 
Switzerland) at 37 ± 0.5 ºC with a rotation speed of 50 rpm. The printed systems were first exposed to 
pH 1.2 for 2 hours. After that, a switch solution was added to achieve pH 7.5 according to a modification 
of a method proposed by Schellekens et al. (2007) [34]. Filtered samples were withdrawn at specific 
interval times (5, 15, 30, 60, 90, 120, 130, 140, 150, 180, 240, 300, 360, 420, 480, 1440 min). The 
percentage of drug released was measured in a UV–Vis spectrophotometer Agilent 8453 (California, 
USA) at 272 nm [33]. The assay was performed in triplicate and sink conditions were met throughout 
the dissolution test. 
Drug release data (Mt/M∞≤ 0.8) were analysed using Microsoft Excel 2010 (Microsoft, Albuquerque, 
NM, USA) according to zero order, Higuchi (1963) [35], Korsmeyer et al. (1983)[36] and Peppas and 
Sahlin (1989) [37] equations (1-3): 
       
𝑀𝑡
𝑀∞
= 𝑘𝑡
1
2⁄      (1) 
𝑀𝑡
𝑀∞
= 𝑘𝑘𝑡
𝑛     (2) 
𝑀𝑡
𝑀∞
= 𝑘𝑑𝑡
𝑚 +  𝑘𝑟𝑡
2𝑚    (3) 
    
where Mt/M∞ is the drug released fraction at time t (the drug loading was considered as M∞), k and 𝑘𝑘 
are kinetic constants characteristic of the drug/polymer system, t is the release time, n is the release 
exponent that depends on the release mechanism and the shape of the matrix tested [38], 𝑘𝑑 and 𝑘𝑟 are 
the diffusion and relaxation rate constants, respectively, m is the purely Fickian diffusion exponent for a 
device of any geometrical shape which exhibits controlled release.  
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Determination coefficient (r
2
) was used to test the applicability of the release models, calculated in linear 
regression for zero order, Higuchi and Korsmeyer equations or quadratic regression for Peppas and 
Sahlin model. 
3. Results and discussion 
3D printed systems have been successfully performed using FDM and IVF. Figure 2 shows the 3D 
printer with FDM extruder and the two syringes of IVF used with drug dispersion and Eudragit FS30D, 
respectively. In order to contain the drug dispersion, the printfill was designed with 2 bottom solid layers 
and 4 sealing perimeters in each layer. Our preliminary studies of printfills with fewer perimeters 
showed drug release from the beginning of the dissolution test, even though the homogeneous Eudragit 
film was present. Therefore, this leads to thinking that there was a radial drug release. Also, perimeter 
speed, infill speed, feeding rate and printing temperature (FDM) were thought to optimize the 
coalescence between the perimetric layers in order to obtain a sealed perimeter. 
                      
Figure 2. A) 3D printer with FDM and IVF technologies; B) Extruder of FDM technology; C) Syringe of IVF technology 
injecting the drug–loaded gel; D) Syringe of IVF technology injecting the delaying release polymer; E) Final printfill 
obtained.  
 
Thereby, drug dispersion was injected at room temperature in PLA extruded structure in the 18th layer. 
With a total of 4 injections, this dispersion was distributed by diffusion inside the internal structure. 
Once dried, theophylline is supposed to be dispersed in the matrix system of the extruded scaffold. On 
the other hand, Eudragit FS30D was injected at the top layer of the scaffold in all the pores of the mesh, 
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in order to ensure that a continuous film was formed. The PLA framework creates a stable structure on 
which the Eudragit can be supported creating a film on the entire top layer. 
SEM microphotographs of printed systems provided useful information about the internal structure of 
printfills (Figure 3). The sealing of the structure was confirmed by the frontal and transversal section of 
perimeters (Figures 3a and 3b), so that, the release of the drug from the printfill depends on the 
homogeneity and uniformity of the Eudragit FS30D film. The width of the enteric film could be 
measured, in the narrowest parts, when the delaying polymer is not deposited on the PLA filament, 
showing values of 149 ± 0.018 μm (Figures 3c and 3d). Also, there is no direct contact between 
theophylline and Eudragit, which can be due to the fact that the three first layers below Eudragit do not 
contain the drug. 
In the case of printed systems without delaying release polymer, as their upper side is not sealed, it is 
possible to observe their internal framework by SEM. Once theophylline dispersion has been completely 
dried drug recrystallized on PLA filaments, as can be seen in Figures 3e and 3f. 
    
    
a) b) 
c) d) 
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Figure 3. SEM microphotographs of printfills with detail of a) frontal view of perimeters, b) transversal section of perimeters, 
c) frontal view of enteric film, d) transversal section of printfill with delaying polymer, e) internal mesh of non-colonic 
printfills with theophylline and f) detail of theophylline crystals on the surface of PLA filaments. 
 
Table 1 shows the weights and dimensions of printfills obtained, according to the digital design. As 
expected, FDM technology offers an accurate and precise manufacturing of 3D printed systems, 
obtaining scaffolds able to hold the content from IVF and helping to control the drug release.  
Table 1. Physical characteristics of printfills obtained. 
 Experimental Theoretical 
Printfill Weight 
(mg) 
Height 
(mm) 
Diameter 
(mm) 
Height 
(mm) 
Diameter 
(mm) 
1 1120.8 7.508 14.819 
7.35 14.00 
2 1053.8 7.330 14.827 
3 1156.2 7.300 14.982 
Mean 1110.3 7.379 14.876 
SD 52.006 0.112 0.092 0.021
a
 0.619
 a
 
CV 4.684 1.524 0.618 0.282
 a
 4.290
 a
 
a, calculated between theoretical and mean of experimental data. 
Enteric polymer supposed 9.5% w/w of the printfill weight. This method has the advantage of the 
addition of the pH-sensitive polymer without the need to use an additional process as a fluid bed or 
coating pan. 
The amount of theophylline injected in the scaffolds was confirmed by drug content assays of the 
printfills as 4.020 ± 0.145 mg, representing a 0.36% w/w from the total weight of the printfill. 
Mean percentages of drug released from printed systems with and without colonic polymer are shown in 
Figure 4. After 2 h in pH 1.2, colonic printed tablets released only 2.3% of theophylline. Once the switch 
solution was added changing pH to 7.5, drug release suddenly increased, suggesting the complete 
e) f) 
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dissolution of the enteric film. Around 80% of drug release was achieved after 8 h of the dissolution test. 
On the other hand, printed systems without enteric polymer showed a fast drug release profile from the 
beginning of the study with more than 60% of drug dissolved in the first 5 minutes. This confirms the 
good sealing and tightness of the printfills, forcing the drug to be released through the upper side when 
the release-delaying polymer is dissolved. Also, homogeneity and uniformity of the Eudragit FS30D 
film has been confirmed with the prolonged drug release obtained from these printfills respect to the 
non-enteric ones. 
 
Figure 4. Mean dissolution profiles from both enteric printfills and non-enteric printfills at different pH values. 
 
Finally, in order to understand the drug release mechanism of the printfills, release data analysis was 
carried out according to zero order, Higuchi (1963), Korsmeyer et al. (1983) and Peppas and Sahlin 
(1989) equations. The values of the main parameters are listed in Table 2. The printfills prepared 
without pH-sensitive polymer showed a fast drug release that did not allow to perform a study of their 
release kinetics -more than 60% of drug content was released in less than 10 min-.  
With respect to the colonic printfills, the obtained results indicate that, after the lag time, the drug is 
released with an intermediate kinetics between zero order and diffusional kinetics, as shown by 
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Korsmeyer time exponent (n=0.8749). In general this kinetic is considered as adequate for sustained 
release. Despite more studies are needed, it could be expected that changing the distribution of the 
components inside the printfills, could lead to different release kinetics and to tailoring release profiles 
for concrete therapeutic needs. 
Table 2. Mathematical modeling and drug release kinetics from enteric printfills. 
b, Higuchi kinetic constant; n, release exponent; kk, Korsmeyer kinetic constant; kd, Peppas diffusion kinetic constant; kr, 
Peppas relaxation kinetic constant; r
2
, determination coefficient. 
 
4. Conclusions 
Pharmaceutical dosage forms have been manufactured for the first time with a 3D printer combining 
Fused Deposition Modelling (FDM) and Injection Volume Filling (IVF). The integration of these two 
techniques allows an easier incorporation of drug/excipient liquid systems to the extruded scaffold at 
room temperature, avoiding other intermediate processes.  
Drug and delaying release polymer dispersions were accurately injected in PLA structure at room 
temperature. In vitro studies show the ability for colon-specific drug delivery of the performed printfills 
thanks to the perfect sealing of the scaffold and the homogeneous layer obtained with the delaying 
release polymer. This way, the advantages of film coating have been obtained without the need of 
performing an additional process in a fluidized bed or coating pan. Even a more complex pharmaceutical 
process, as is the partial coating of a dosage form, has been easily performed in one step. 
IVF technology complements FDM, solving the main limitations of this technique -as high temperature 
and difficult drug loading- and thus, providing a versatile platform for drug delivery. Moreover, IVF will 
allow placing the drug in specific and known sites inside the scaffold, offering a wide spectrum of 
possibilities in pharmaceuticals for these new dosage forms. 
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